All PlansCoverageMedium impact
Prostate Specific Antigen (PSA)
Blue Cross & Blue Shield of Mississippi·MS · Urology, Family Medicine, Internal Medicine +1 more·Medical Policy
We identified it
Jun 20, 2026
Summary
This is a comprehensive PSA testing policy that establishes medical necessity criteria for prostate cancer screening and monitoring. The policy requires shared decision-making for screening, limits testing frequency (annually for symptomatic patients, every 2 years for screening), and specifies high-risk categories starting screening at ages 40-45 versus age 50 for average risk.
Action Required
Immediately: Review PSA test orders to ensure compliance with frequency limitations - maximum once per year for symptomatic patients, maximum every 2 years for screening. Providers must document shared decision-making discussion for all screening PSA tests. Update EMR templates to capture high-risk factors (Black race, family history under 65, BRCA mutations) and urinary symptoms. Claims may be denied if testing exceeds frequency limits or lacks proper documentation.